Our further analysis has pointed to the enrichment of MHCII-associated antigen-processing and presentation pathway post-therapy and in the longest survivor, which led us to hypothesize that anti-tumor CD4+ T cells are involved in response to oHSV therapy. The gene discussed is CD4; the disease is neoplasm.